Psoriasis

American Family Physician

Volumn 87, Issue 9, 2013, Pages 626-633

  Weigle, Nancy ^a   Mcbane, Sarah ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CALCINEURIN INHIBITOR; CALCIPOTRIOL; CALCITRIOL; COAL TAR; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DITHRANOL; ETANERCEPT; ETRETIN; FOLIC ACID; HYDROXYUREA; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PIMECROLIMUS; SALAZOSULFAPYRIDINE; SALICYLIC ACID; TABLOID; TACROLIMUS; TAZAROTENE; TIOGUANINE; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; USTEKINUMAB; VACCINE; VITAMIN D DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

ARTICLE; BURN; CARDIOVASCULAR DISEASE; COMORBIDITY; DACTYLITIS; DEPRESSION; DISEASE ASSOCIATION; DRUG WITHDRAWAL; ENVIRONMENTAL FACTOR; ERYTHEMA; GROUP A STREPTOCOCCAL INFECTION; GUTTATE PSORIASIS; HEART INFARCTION; HEREDITY; HUMAN; HYPERCALCEMIA; HYPERLIPIDEMIA; IMMUNE MEDIATED INJURY; LYMPHOMA; METABOLIC SYNDROME X; MORBIDITY; NAIL DISEASE; OBESITY; PATHOPHYSIOLOGY; PATIENT MONITORING; PHARYNGITIS; PHOTOTHERAPY; PRURITUS; PSORIASIS; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SIDE EFFECT; SKIN ATROPHY; SKIN BIOPSY; SKIN CANCER; SKIN DEFECT; SKIN IRRITATION; SMOKING; SYSTEMATIC REVIEW (TOPIC); TACHYPHYLAXIS; TUBERCULIN TEST; ULTRAVIOLET RADIATION; UNSPECIFIED SIDE EFFECT; WOUND HEALING IMPAIRMENT; PATIENT EDUCATION; CLASSIFICATION; DRUG POTENTIATION; FEMALE; MALE; REVIEW;

HUMANS; PSORIASIS; ADRENAL CORTEX HORMONES; FEMALE; MALE; PHOTOTHERAPY; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VITAMIN D;

MLCS; MLOWN;

EID: 84877090335     PISSN: 0002838X     EISSN: 15320650     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol. 2007; 25(6):535-546.
2. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(suppl 2):ii18-ii23.
3. Capon F, Trembath RC, Barker JN. An update on the genetics of psoriasis. Dermatol Clin. 2004;22(4):339-347.
4. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-850.
5. Kimball AB, Gladman D, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008;58(6):1031-1042.
6. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263-271.
7. Habif TP. Psoriasis and other papulosquamous diseases. In: Clinical Dermatology. 5th ed. Hanover, N.H.: Mosby Elsevier; 2010:264-275.
8. Reich K. Approach to managing patients with nail psoriasis. J Eur Acad Dermatol Venereol. 2009;23(suppl 1):15-21.
9. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58(5):851-864.
10. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665-2673.
11. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137(3):280-284.
12. Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol. 2004;51(5):704-708.
13. Horn EJ, Fox KM, Patel V, Kimball AB, Gordon KB, Lebwohl MG. Treatment satisfaction and health-related quality of life among individuals with psoriasis: National Psoriasis Foundation Survey Findings. Psoriasis Forum. 2008;14(2):27-34.
14. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 pt 1):401-407.
15. Hsu S, Papp KA, Lebwohl MG, et al.; National Psoriasis Foundation Medical Board. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012;148(1):95-102.
16. Menter A, Korman NJ, Elmets CA, et al.; American Academy of Dermatology. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009; 60(4):643-659.
17. Drugdex system. http://thomsonreuters.com/products_services/healthcare/healthcare_products/a-z/drugdex_system/. Accessed May 8, 2012
18. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2010;62(1):114-135.
19. Stelara (ustekinumab) [package insert]. Horsham, Pa.: Janssen Biotech; 2012. http://www.stelarainfo.com/pdf/PrescribingInformation.pdf. Accessed May 8, 2012.
20. Clinical pharmacology. http://www.clinicalpharmacology.com [login required]. Accessed January 4, 2012.
21. Del Rosso JQ, Kim GK. The rationale behind topical vitamin D analogs in the treatment of psoriasis: where does topical calcitrol fit in? J Clin Aesthetic Derm. August 2010. http://www.jcadonline.com/the-rationale-behind-topical-vitamin-d-analogs-in-the-treatment-of-psoriasis-where-does-topical-calcitriol-fit-in/. Accessed May 8, 2012.
22. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451-485.